Furthermore, TNBC patients with higher expression of ERO1 had a higher risk of tumor recurrence and metastatic spread [23] indicating that ERO1A might be a biomarker for poor breast cancer prognosis and a target for cancer therapy. This evidence concerns the gene ERO1A and neoplasm.